ed for use through 3/31/2007. OMB 0651-0021

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER

033393-055184 U.S. APPLICATION NO. 11 know, spe 37 CFR 1.5)

INTERNATIONAL APPLICATION NO.

INTERNATIONAL FILING DATE

PRIORITY DATE CLAIMED


PCT/US03/034424 29 October 2003 (29.10.2003) 29 October 2002 (29.10.2002)					
TITLE OF INVENTION INHIBITION OF GENE EXPRESSION USING RNA INTERFERING AGENTS					
APPLICANT(S) FOR DO/EO/US THE CENTER FOR BLOOD RESEARCH, INC.; LIEBERMAN, Judy, SHANKAR, Premlata, NARASIMHASWAMY, Manjunath, SONG, Erwei, LEE, Sang-Kyung					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
1. X This is a FIRST submission of items concerning a submission under 35 U.S.C. 371.					
2. This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371.					
3. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.					
4. The US has been elected (Article 31).					
5. X A copy of the International Application as filed (35 U.S.C. 371(c)(2))					
a. is attached hereto (required only if not communicated by the International Bureau).					
b. $\overline{f X}$ has been communicated by the International Bureau.					
c. is not required, as the application was filed in the United States Receiving Office (RO/US).					
6. An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).					
a. is attached hereto.					
b. has been previously submitted under 35 U.S.C. 154(d)(4).					
7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))					
a. are attached hereto (required only if not communicated by the International Bureau).					
b. have been communicated by the International Bureau.					
c. have not been made; however, the time limit for making such amendments has NOT expired.					
d. have not been made and will not be made.					
8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).					
9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).					
An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).					
Items 11 to 20 below concern document(s) or information included:					
11. X An Information Disclosure Statement under 37 CFR 1.97 and 1.98.					
12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.					
13. X A preliminary amendment.					
14. An Application Data Sheet under 37 CFR 1.76.					
15. A substitute specification.					
16. A power of attorney and/or change of address letter.					
17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825.					
18. A second copy of the published International Application under 35 U.S.C. 154(d)(4).					
19. A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).					
20. X Other items or information: Express Mail Cent. EV653000539US; COPY-Int'l Search Report; Reference C1 and Return Receipt Postcard.					

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Page 1 of 2

JC20 Rec'd PCT/PTO 2 OTG/110 Res (14805)
Approved for use mrough 3/31/2007, DMR 0615-021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO. (if known, see 37 CFR 1.5) INTERNATIONAL APPLICATION NO.			ATTORNEY'S DOCKET NUMBER				
17d be 25006 21 PCT/US03/034424		033393-055184					
The following fees have been submitted				CALCULATIONS	PTO USE ONLY		
21. 🔀 Basic national fee\$300					\$ 300.00)	
22. X Examination fee If International preliminary examination report prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4)					\$ 200.00		
23. X Search fee Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority					100.00		
TOTAL OF 21, 22 and 23 =					\$ 600.00	,	
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.					333.03		
Total Sheets	Extra Sheets		additional 50 or fraction ip to a whole number)	RATE	·		
- 100 =	/50 =			× \$250	\$ 0.00		
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(h)).					\$ 130.00		
CLAIMS	NUMB	ER FILED	NUMBER EXTRA	RATE	\$		
Total claims		15 - 20 =	· .	× \$ 50	\$		
Independent clair	ms	2 -3=		× \$200	\$	1	
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$360					\$	†	
TOTAL OF ABOVE CALCULATIONS =					\$ 730.00		
Applicant claims small entity status. See 37 CFR 1.27. Fees above are reduced by ½.					730.00		
SUBTOTAL =					\$ 365.00	. '	
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).					\$	0.00	
TOTAL NATIONAL FEE =					\$		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +					\$	0.00	
TOTAL FEES ENCLOSED =					\$	365,.00	
	· · · ·				Amount to be refunded:	\$	
		•			Amount to be charged:	\$	
a. X A check in the amount of \$ 365.00 to cover the above fees is enclosed.							
b. Please charge my Deposit Account No in the amount of \$ to cover the above fees. A duplicate copy of this sheet is enclosed.							
c. X The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No50-0850 A duplicate copy of this sheet is enclosed.							
d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.							
NOTE: Where ar	appropriate time	e limit under 37 C	FR 1.495 has not been me		(37 CFR 1.137(a) or (b))	must be filed	
and granted to restore the International Application to pending status.							
David S. Resnick							
NIXON PEABODY LLP							
100 Summer Street David S. Res					snick	<u> </u>	
Boston, MA 02110							
US 34,235 REGISTRATION NUMBER							



Practitioner's Docket No. 033393-055184

PCT/US03/34424	29 October 2003 (29.10.2003)	29 October 2002 (29.10.2002)	
International Application Number	International Filing Date	International Earliest Priority Date	

TITLE OF INVENTION: INHIBITION OF GENE EXPRESSION USING RNA **INTERFERING AGENTS**

APPLICANT(S) FOR EO/DO: THE CENTER FOR BLOOD RESEARCH, INC. INVENTOR(S)/APPLICANT(S) FOR US: LIEBERMAN, Judy, SHANKAR, Premlata,

NARASIMHASWAMY, Manjunath, SONG, Erwei,

LEE, Sang-Kyung

VERIFIED CERTIFICATION OF EXPRESS MAILING DATE (INTERNATIONAL APPLICATION (37 C.F.R. section 1.10(c))

I declare that, on April 2005 I deposited, with the United States Postal Service, in an envelope "Express Mail, Post Office to Addressee," bearing Label Number EV653000539US, addressed to the "MAIL STOP PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450," and having an express mail certification that I executed, the following papers:

- Express Mail Certificate EV653000539 US (1 pg.); 1.
- 2. Transmittal Letter to the U.S. Receiving Office Concerning a Filing Under 35 U.S.C. 371 (duplicate pg. 2) (3 pp.);
- Application Data Sheet (5 pp.); 3.
- 4. Preliminary Amendment (5 pp.);
- 5. COPY-Published PCT WO 2004/039957 A3 (coversheet only)(1 pg.);
- 6. International Search Report - Form PCT/ISA 210 (2 pp.);
- 7. Information Disclosure Statement, including Forms 1449A/PTO (4 pp.);
- 8. COPY - Reference C1;
- 9. Check - \$365.00; and
- 10. Return Receipt Postcard.

A copy of these papers from the file of this application is attached.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application of any patent issuing thereon.

Debra J. Kellom

(type or print name of person certifying)